Study: NCT04484337

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Cabotegravir sodium (Oral Lead In)
Description: CAB will be available as 30 mg tablets for oral administration.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cabotegravir sodium (Oral Lead In)
Description: CAB will be available as 30 mg tablets for oral administration.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cabotegravir sodium (Oral Lead In)
Description: CAB will be available as 30 mg tablets for oral administration.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Cabotegravir sodium (Oral Lead In)
Description: CAB will be available as 30 mg tablets for oral administration.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cabotegravir sodium (Oral Lead In)
Description: CAB will be available as 30 mg tablets for oral administration.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Cabotegravir sodium (Oral Lead In)
Description: CAB will be available as 30 mg tablets for oral administration.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cabotegravir sodium (Oral Lead In)
Description: CAB will be available as 30 mg tablets for oral administration.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Cabotegravir sodium (Oral Lead In)
Description: CAB will be available as 30 mg tablets for oral administration.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cabotegravir sodium (Oral Lead In)
Description: CAB will be available as 30 mg tablets for oral administration.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Cabotegravir sodium (Oral Lead In)
Description: CAB will be available as 30 mg tablets for oral administration.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cabotegravir sodium (Oral Lead In)
Description: CAB will be available as 30 mg tablets for oral administration.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Cabotegravir sodium (Oral Lead In)
Description: CAB will be available as 30 mg tablets for oral administration.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cabotegravir sodium (Oral Lead In)
Description: CAB will be available as 30 mg tablets for oral administration.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Cabotegravir sodium (Oral Lead In)
Description: CAB will be available as 30 mg tablets for oral administration.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cabotegravir sodium (Oral Lead In)
Description: CAB will be available as 30 mg tablets for oral administration.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cabotegravir 400 mg/mL
Description: CAB 400 mg/mL will be available for administration by IM injection or SC Injection.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cabotegravir 400 mg/mL
Description: CAB 400 mg/mL will be available for administration by IM injection or SC Injection.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cabotegravir 400 mg/mL
Description: CAB 400 mg/mL will be available for administration by IM injection or SC Injection.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cabotegravir 400 mg/mL
Description: CAB 400 mg/mL will be available for administration by IM injection or SC Injection.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cabotegravir 400 mg/mL
Description: CAB 400 mg/mL will be available for administration by IM injection or SC Injection.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cabotegravir 400 mg/mL
Description: CAB 400 mg/mL will be available for administration by IM injection or SC Injection.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cabotegravir 400 mg/mL
Description: CAB 400 mg/mL will be available for administration by IM injection or SC Injection.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cabotegravir 400 mg/mL
Description: CAB 400 mg/mL will be available for administration by IM injection or SC Injection.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Cabotegravir 200 mg/mL
Description: CAB 200 mg/mL will be available for administration by IM injection or SC Injection.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Cabotegravir 200 mg/mL
Description: CAB 200 mg/mL will be available for administration by IM injection or SC Injection.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Cabotegravir 200 mg/mL
Description: CAB 200 mg/mL will be available for administration by IM injection or SC Injection.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Cabotegravir 200 mg/mL
Description: CAB 200 mg/mL will be available for administration by IM injection or SC Injection.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Cabotegravir 200 mg/mL
Description: CAB 200 mg/mL will be available for administration by IM injection or SC Injection.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Cabotegravir 200 mg/mL
Description: CAB 200 mg/mL will be available for administration by IM injection or SC Injection.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Cabotegravir 200 mg/mL
Description: CAB 200 mg/mL will be available for administration by IM injection or SC Injection.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Topical non-steroidal anti-inflammatory drug
Description: Non-steroidal anti-inflammatory drug will be available for topical application

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Topical steroid
Description: Steroid will be available for topical application

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo creams/gels
Description: Placebo creams/gels will be available for topical application

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Recombinant human hyaluronidase PH20 (rHuPH20)
Description: rHuPH20 will be available for administration by SC Injection

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Recombinant human hyaluronidase PH20 (rHuPH20)
Description: rHuPH20 will be available for administration by SC Injection